I’ve been reviewing data on biopharma business trends for 16 years now, and no one does the number crunching better than Chris Dokomajilar at DealForma. I’ve seen the data pressure tested repeatedly, and it is solid. We’re proud to have him contribute regular pieces to Endpoints News.